When was Prometheus Biosciences founded?

Prometheus Biosciences was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Prometheus Biosciences located?

Prometheus Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Prometheus Biosciences have?

As of Mar 01, 2026, the latest employee count at Prometheus Biosciences is 10 - 49.

Is Prometheus Biosciences a funded company?

Prometheus Biosciences is a funded company, having raised a total of $***** in its 1st and only funding round, a Series D round on Nov 09, 2020.

How much is Prometheus Biosciences worth?

The last known valuation of Prometheus Biosciences was $***** as of Mar 11, 2021.

When was the latest funding round of Prometheus Biosciences?

Prometheus Biosciences' latest funding was a $***** Series D round on Nov 09, 2020, with participation from 10 investors.

What is the annual revenue of Prometheus Biosciences?

Annual revenue of Prometheus Biosciences is between $1M and $10M as on Dec 31, 2022

Where does Prometheus Biosciences rank among its competitors?

Prometheus Biosciences ranks 14th amongst 59 active competitors, of which 25 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was MRM Health, which secured $3.03M in May, 2026.

Who are the top competitors of Prometheus Biosciences?

Prometheus Biosciences' top competitors include Quell, Enveda and Kanvas Biosciences. Among them, MRM Health secured the most recent funding round in May, 2026.

Prometheus Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Prometheus Biosciences is developing drugs for gastrointestinal diseases. The company has clinical biobank with medical records that have enabled the identification of targets for the treatment of patients with biomarker-defined subclinical GI phenotypes. The company is mainly focused on bowel-related diseases. The pipelined products are currently in the clinical trial phage.

Website: prometheusbiosciences.com
Social
Email ID: *****@prometheusbiosciences.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

2016

Location

San Diego, United States

Stage

Acquired

Total Funding

$130M in 1 round

Latest Funding Round

Series D, Nov 09, 2020, $*****

Last Known Valuation

$***** as on Mar 11, 2021

Investors

Eventide Funds & 10 more

Ranked

14^th among 59 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2022

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Quell & 53 more

Exit Details

Acquired by Merck (Apr 16, 2023)

View Prometheus Biosciences' full profile

Prometheus Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Prometheus Biosciences, Inc. CIN: 1718852 , United States, Active	Oct 09, 2017	$1M - $10M (As on Dec 31, 2022)	-	-
PRECISION IBD, INC. CIN: 814282653 , United States, Active	Dec 31, 1999	-	86 (As on Dec 31, 2022)	-

Prometheus Biosciences got acquired by Merck on Apr 16, 2023.

Click here to take a look at Prometheus Biosciences's acquisition in detail

Prometheus Biosciences has raised a total funding of $130M over 1 round. Its latest funding round was a Series D round on Nov 09, 2020 for $*****. 10 investors participated in its latest round. Prometheus Biosciences has 11 institutional investors.

Here is the list of recent funding rounds of Prometheus Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 09, 2020	3128520	Series D	3733839	1703392	7451300	7421163

Access funding benchmarks and valuations. Sign up today!

View details of Prometheus Biosciences's funding rounds and investors

The founders of Prometheus Biosciences are Scott L Glenn and Stephan Targan.

Here are the details of Prometheus Biosciences' key team members:

Scott L Glenn: Former Co-Founder of Prometheus Biosciences and founder of 2 other companies, GLO Pharma and Windamere Venture Partners.
Contact Info: 1 email address
Stephan Targan: Co-Founder of Prometheus Biosciences.

View details of Prometheus Biosciences's Founder profiles and Board Members

Prometheus Biosciences' employee count trend

Prometheus Biosciences has 10 - 49 employees as of Mar 26. Here is Prometheus Biosciences's employee count trend over the years:

Employee count trend for Prometheus Biosciences

Uncover Prometheus Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prometheus Biosciences include Quell, Enveda and Kanvas Biosciences. Here is the list of Top 10 competitors of Prometheus Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
2nd	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 30 others	63/100
3rd	Kanvas Biosciences 2021, Ithaca (United States), Series A	Provider of imaging solutions for microbial research and infectious diseases	$77.5M	DCVC, Uncommon Denominator & 11 others	63/100
4th	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	62/100
5th	Accropeutics 2017, Suzhou (China), Series C	Developer of drugs for inflammation, autoimmune diseases, and cancer	$62M	Orbimed, Shenzhen Capital Group & 7 others	58/100
6th	MRM Health 2020, Ghent (Belgium), Series B	Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases	$79.2M	DuPont, Ackermans & van Haaren & 11 others	58/100
7th	OMass Therapeutics 2016, Oxford (United Kingdom), Series B	Developer of therapeutics for immunological and orphan diseases	$166M	Google Ventures, Sanofi Ventures & 6 others	57/100
8th	Protagonist Therapeutics 2001, Milpitas (United States), Public	Developer of oral peptide therapeutics for gastrointestinal diseases	$67M	Lilly Ventures, Johnson & Johnson Innovation – JJDC ... & 12 others	56/100
9th	Athos Therapeutics 2019, Torrance (United States), Series A	Developer of AI-based therapeutics for treating autoimmune diseases	$38.3M	-	56/100
10th	Aclaris Therapeutics 2012, Malvern (United States), Public	Biopharmaceutical company empowering patients through therapeutic innovation in immuno-inflammatory conditions	$82M	F-Prime Capital, RA Capital Management & 13 others	55/100
14th	Prometheus Biosciences 2016, San Diego (United States), Acquired	Developer of drugs for gastrointestinal diseases	$130M	RTW Investments, Cowen & 9 others	54/100